GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medite Cancer Diagnostics Inc (OTCPK:MDIT) » Definitions » 14-Day RSI

Medite Cancer Diagnostics (Medite Cancer Diagnostics) 14-Day RSI : N/A (As of Jun. 15, 2024)


View and export this data going back to . Start your Free Trial

What is Medite Cancer Diagnostics 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-06-15), Medite Cancer Diagnostics's 14-Day RSI is N/A.

The industry rank for Medite Cancer Diagnostics's 14-Day RSI or its related term are showing as below:

MDIT's 14-Day RSI is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 45.39
* Ranked among companies with meaningful 14-Day RSI only.

Competitive Comparison of Medite Cancer Diagnostics's 14-Day RSI

For the Medical Instruments & Supplies subindustry, Medite Cancer Diagnostics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medite Cancer Diagnostics's 14-Day RSI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medite Cancer Diagnostics's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Medite Cancer Diagnostics's 14-Day RSI falls into.



Medite Cancer Diagnostics  (OTCPK:MDIT) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medite Cancer Diagnostics  (OTCPK:MDIT) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Medite Cancer Diagnostics 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Medite Cancer Diagnostics's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Medite Cancer Diagnostics (Medite Cancer Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
4203 SouthWest 34th Street, Orlando, FL, USA, 32811
Medite Cancer Diagnostics Inc is a US-based company which specializes in the marketing and selling of MEDITE core products (instruments and consumables), manufacturing, development of new solutions in histology and cytology and marketing of molecular biomarkers. The company manufactures medical devices and consumables are for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. Medite operates through the single segment for cancer diagnostics instruments and consumables for histology and cytology laboratories. It offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis.
Executives
Lewis William Austin Iv director, 10 percent owner 201 E 87TH STREET, APT 5H, NEW YORK NY 10128
John H Abeles director 2365 NW 41ST STREET BOCA RATON FL 33431
Joel S Kanter director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Clinton Severson director C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587

Medite Cancer Diagnostics (Medite Cancer Diagnostics) Headlines

No Headlines